Abstract:Ethnopharmacological relevanceXiang-lian pill, consisting of Coptis chinensis Franch. coprocessed with Tetradium ruticarpum (A.Juss.) T.G.Hartley (Yu-huang-lian) and Aucklandia lappa DC. (Mu-xiang), is traditionally used to relieve fever, abdominal pain, and gastrointestinal inflammatory symptoms observed in patients with malignancies of the gastrointestinal tract. Each of the three herbs contained in Xiang-lian pill has been indicated to have anticancer effects on a variety of cancers, but its effects on pancreatic cancer remain unexplored. The main extracts of these herbs have anti-pancreatic cancer effects, but the comprehensive mechanism of this compound prescription of Xiang-lian pill in pancreatic cancer remains to be revealed.Aim of the studyTo explore the main active ingredients, potential anti-pancreatic cancer targets, and related mechanisms of the Xiang-lian pill and to determine its therapeutic value in vivo.Materials and methodsNetwork pharmacology and bioinformatics analysis were applied to screen the potential effective ingredients and key targets. Liquid/gas-mass spectrometry was performed for ingredients validation. Molecular docking and the cellular thermal shift assay were performed to test the binding efficiency between ingredients and targets. A murine pancreatic cancer model was established and administered different doses of the Xiang-lian pill. Hematoxylin-eosin staining was used for histopathological observation. Immunohistochemistry and immunoblotting were conducted for target validation. In vitro studies (cell viability and clonogenicity assays) were conducted to investigate the impact of three main ingredients in Xiang-lian pill on pancreatic cancer cells. PTGS2 overexpression was performed to reversely confirm the antitumor mechanisms of rutaecarpine as a specific PTGS2 inhibitor.ResultsXiang-lian pill suppressed pancreatic cancer growth in the dose range of 0.78-2.34g/kg with no significant toxicity. Sixteen potentially active ingredients and 26 corresponding therapeutic targets for pancreatic cancer were identified. PTGS2, PTGS1, KCNH2, PRSS1, and HSP90AA1 were the top 5 significant genes targeted by the Xiang-lian pill. Evodiamine, rutaecarpine and stigmasterol bound to PTGS2 and PTGS1 with different affinities and inhibited pancreatic cancer cell proliferation. The PTGS2-associated metabolic pathway MEK/ERK was downregulated by rutaecarpine in vitro and the Xiang-lian pill in vivo.ConclusionsXiang-lian pill mainly regulates inflammation, apoptosis, metastasis, and metabolism to exert an antitumor effect. The main active ingredients in Xiang-lian pill exhibit antitumor roles through directly binding to key targets in pancreatic cancer. PTGS2 mediated MEK/ERK inhibition by rutaecarpine represents a key therapeutic mechanism of Xiang-lian pill.

Xanthatin Suppresses Pancreatic Cancer Cell Growth via the ROS/RBL1 Signaling Pathway: In Vitro and In Vivo Insights

Xanthatin inhibits non-small cell lung cancer proliferation by breaking the redox balance

Xanthatin Mediates G(2)/M Cell Cycle Arrest, Autophagy And Apoptosis Via Ros/Xiap Signaling In Human Colon Cancer Cells

Xanthatin Induces G2/M Cell Cycle Arrest and Apoptosis in Human Gastric Carcinoma Mkn-45 Cells

Xanthatin Induce DDP-resistance Lung Cancer Cells Apoptosis Through Regulation of GLUT1 Mediated ROS Accumulation.

Xanthotoxol Suppresses Non-Small Cell Lung Cancer Progression and Might Improve Patients’ Prognosis

Xanthatin induces cell cycle arrest at G2/M checkpoint and apoptosis via disrupting NF-κB pathway in A549 non-small-cell lung cancer cells.

Targeting X-linked Inhibitor of Apoptosis Protein Inhibits Pancreatic Cancer Cell Growth Through P-Akt Depletion.

Xanthorrhizol Inhibits Non‐small Cell Carcinoma (A549) Cell Growth and Promotes Apoptosis Through Modulation of PI3K/AKT and NF‐κB Signaling Pathway

TMT-Based Quantitative Proteomic Analysis Identified Proteins and Signaling Pathways Involved in the Response to Xanthatin Treatment in Human HT-29 Colon Cancer Cells

Xanthatin induces glioma cell apoptosis and inhibits tumor growth via activating endoplasmic reticulum stress-dependent CHOP pathway

Chloroxine inhibits pancreatic cancer progression through targeted antagonization of the PI3K/AKT/mTOR signaling pathway

Xanthatin, a Novel Potent Inhibitor of VEGFR2 Signaling, Inhibits Angiogenesis and Tumor Growth in Breast Cancer Cells.

The Combination of Cantharidin and Antiangiogenic Therapeutics Presents Additive Antitumor Effects Against Pancreatic Cancer

Xanthatin Induces Apoptosis by Activating Endoplasmic Reticulum Stress in Hepatoma Cells

Mechanisms of pancreatic tumor suppression mediated by Xiang-lian pill: An integrated in silico exploration and experimental validation

Xanthatin Triggers Chk1-mediated DNA Damage Response and Destabilizes Cdc25C Via Lysosomal Degradation in Lung Cancer Cells

A Natural Xanthone Suppresses Lung Cancer Growth and Metastasis by Targeting STAT3 and FAK Signaling Pathways

Xanthatin Selectively Targets Retinoblastoma by Inhibiting the PLK1-Mediated Cell Cycle

Anticancer Effect Of Szc015 On Pancreatic Cancer Via Mitochondria-Dependent Apoptosis And The Constitutive Suppression Of Activated Nuclear Factor B And Stat3 In Vitro And In Vivo

ATF4/TXNIP/REDD1/mTOR Signaling Mediates the Antitumor Activities of Liver X Receptor in Pancreatic Cancers